During ageing, Rubicon is upregulated in the liver and kidney which exacerbate age-related disease including NAFLD and kidney fibrosis, while Rubicon is downregulated in adipose tissue which is also closely associated age-related phenotype including lipodystrophy, insulin resistance and ectopic fat accumulation (Table 1). Here, RUBCN is linked to metabolic dysfunction-associated steatotic liver disease.